- Recommendation ID
- TA455/1
- Question
Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.
- Any explanatory notes
(if applicable) N/A
Source guidance details
- Comes from guidance
- Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- Number
- TA455
- Date issued
- July 2017
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/07/2017 |